Claims
- 1. A method of inhibiting metastases of a primary tumor to a liver tissue, comprising directly contacting said liver tissue with taurolidine.
- 2. The method of claim 1, wherein said primary tumor is not a liver tumor.
- 3. The method of claim 1, wherein said primary tumor is in an organ of the peritoneal cavity.
- 4. The method of claim 1, further comprising identifying an individual who is at risk of developing a metastatic liver tumor.
- 5. The method of claim 4, wherein said individual is a mammal.
- 6. The method of claim 5, wherein said mammal is a human.
- 7. The method of claim 1, wherein said individual is identified as suffering from a colorectal tumor.
- 8. The method of claim 1, wherein said individual is identified as suffering from a tumor selected from the group consisting of a lung tumor, breast tumor, kidney tumor, colon tumor, esophageal tumor, testicular tumor, pancreatic tumor, melanoma, and choriocarcinoma.
- 9. The method of claim 1, wherein said liver is isolated from systemic circulation prior to contacting with said Taurolidine.
- 10. The method of claim 1, wherein said liver is perfused with said taurolidine in situ.
- 11. The method of claim 1, wherein liver blood circulation is essentially isolated from systemic blood circulation.
- 12. The method of claim 1, wherein said perfusion is performed prior to excision of a primary tumor.
- 13. The method of claim 1, wherein said perfusion is carried out in conjunction with an abdominal surgery.
- 14. The method of claim 1, wherein said Taurolidine is administered by in-dwelling catheter.
- 15. The method of claim 1, wherein said Taurolidine is administered at a dose which increased caspase activity in a cell.
- 16. The method of claim 1, wherein said Taurolidine is administered intravenously.
PRIORITY INFORMATION
[0001] This application claims priority to provisional patent application U.S. Ser. No. 60/326,288, filed on Oct. 1, 2001, the entire contents of which is hereby incorporated by reference.
STATEMENT AS TO FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with U.S. government support under National Institutes of Health grant number CA-35711 and AA002666. The government has certain rights in the invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60326288 |
Oct 2001 |
US |